Yếu tố VIII tái tổ hợp dạng pegyl hóa, toàn phần cho điều trị dự phòng và theo nhu cầu đối với bệnh nhân hemophilia A nặng

Srivastava, 2013, Guidelines for the management of hemophilia., Haemophilia, 19, e1, 10.1111/j.1365-2516.2012.02909.x

National Hemophilia Foundation

National Hemophilia Foundation

Björkman, 2001, Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia., Clin Pharmacokinet, 40, 815, 10.2165/00003088-200140110-00003

Björkman, 2009, Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A., Eur J Clin Pharmacol, 65, 989, 10.1007/s00228-009-0676-x

Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia., N Engl J Med, 357, 535, 10.1056/NEJMoa067659

White, 1997, A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A., Thromb Haemost, 77, 660, 10.1055/s-0038-1656030

Björkman, 2003, Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective., Haemophilia, 9, 101, 10.1046/j.1365-2516.9.s1.4.x

Valentino, 2012, A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management., J Thromb Haemost, 10, 359, 10.1111/j.1538-7836.2011.04611.x

Lillicrap, 2010, Improvements in factor concentrates., Curr Opin Hematol, 17, 393, 10.1097/MOH.0b013e32833c06c6

Fogarty, 2011, Biological rationale for new drugs in the bleeding disorders pipeline., Hematology Am Soc Hematol Educ Program, 2011, 397, 10.1182/asheducation-2011.1.397

Mahlangu, 2014, Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A., Blood, 123, 317, 10.1182/blood-2013-10-529974

Harris, 2003, Effect of pegylation on pharmaceuticals., Nat Rev Drug Discov, 2, 214, 10.1038/nrd1033

Turecek, 2012, BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation., Hamostaseologie, 32, S29

ICH Expert Working Group

Rentz, 2009, Psychometric evaluation of a patient-reported symptom assessment tool for adults with haemophilia (the HAEMO-SYM)., Haemophilia, 15, 1039, 10.1111/j.1365-2516.2008.01955.x

Mannucci, 2013, Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial., Blood, 122, 648, 10.1182/blood-2013-01-479527

Fijnvandraat, 1995, Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels., Br J Haematol, 91, 474, 10.1111/j.1365-2141.1995.tb05325.x

Lalezari, 2014, Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS., Haemophilia, 20, e15, 10.1111/hae.12294

Berntorp, 2014, Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method., Biologics, 8, 115

Blanchette, 2008, Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients., J Thromb Haemost, 6, 1319, 10.1111/j.1538-7836.2008.03032.x

Tarantino, 2004, Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A., Haemophilia, 10, 428, 10.1111/j.1365-2516.2004.00932.x

Shapiro, 2009, Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A., Expert Opin Biol Ther, 9, 273, 10.1517/14712590902729392